Stock analysts at Evercore ISI began coverage on shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) in a research report issued on Wednesday, Marketbeat.com reports. The firm set an “in-line” rating and a $63.00 price target on the biopharmaceutical company’s stock. Evercore ISI’s price target points to a potential upside of 2.71% from the company’s previous close.

Several other brokerages have also commented on RARE. Zacks Investment Research raised Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Tuesday, July 18th. SunTrust Banks, Inc. boosted their price objective on Ultragenyx Pharmaceutical from $100.00 to $105.00 and gave the stock a “buy” rating in a report on Wednesday, April 19th. Robert W. Baird reissued an “outperform” rating and set a $90.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday, April 19th. Canaccord Genuity set a $98.00 price objective on Ultragenyx Pharmaceutical and gave the stock a “buy” rating in a report on Friday, July 28th. Finally, BidaskClub lowered Ultragenyx Pharmaceutical from a “buy” rating to a “hold” rating in a report on Tuesday, August 1st. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and eight have given a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $83.50.

Shares of Ultragenyx Pharmaceutical (NASDAQ RARE) traded down 1.78% on Wednesday, reaching $60.25. 30,676 shares of the company were exchanged. The firm’s market capitalization is $2.56 billion. Ultragenyx Pharmaceutical has a 12-month low of $51.67 and a 12-month high of $91.35. The stock’s 50-day moving average is $64.71 and its 200 day moving average is $66.97.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($1.72) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.73) by $0.01. During the same period in the previous year, the business posted ($1.46) EPS. On average, analysts forecast that Ultragenyx Pharmaceutical will post ($7.24) EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/08/16/ultragenyx-pharmaceutical-inc-rare-now-covered-by-analysts-at-evercore-isi.html.

In other Ultragenyx Pharmaceutical news, VP Theodore Alan Huizenga sold 480 shares of the business’s stock in a transaction that occurred on Friday, May 26th. The stock was sold at an average price of $57.46, for a total value of $27,580.80. Following the completion of the sale, the vice president now owns 9,366 shares in the company, valued at $538,170.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 9.20% of the company’s stock.

Several institutional investors have recently made changes to their positions in RARE. FMR LLC increased its position in shares of Ultragenyx Pharmaceutical by 3.9% in the first quarter. FMR LLC now owns 6,110,627 shares of the biopharmaceutical company’s stock worth $414,178,000 after buying an additional 227,802 shares in the last quarter. Capital Research Global Investors increased its position in shares of Ultragenyx Pharmaceutical by 1.4% in the second quarter. Capital Research Global Investors now owns 5,183,330 shares of the biopharmaceutical company’s stock worth $321,937,000 after buying an additional 71,811 shares in the last quarter. BlackRock Inc. increased its position in shares of Ultragenyx Pharmaceutical by 10.4% in the second quarter. BlackRock Inc. now owns 3,497,591 shares of the biopharmaceutical company’s stock worth $217,237,000 after buying an additional 330,911 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Ultragenyx Pharmaceutical by 4.5% in the second quarter. Vanguard Group Inc. now owns 3,130,273 shares of the biopharmaceutical company’s stock worth $194,421,000 after buying an additional 135,335 shares in the last quarter. Finally, Capital International Investors increased its position in shares of Ultragenyx Pharmaceutical by 9.1% in the second quarter. Capital International Investors now owns 2,374,985 shares of the biopharmaceutical company’s stock worth $147,510,000 after buying an additional 198,252 shares in the last quarter. Institutional investors own 95.71% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.